Chengdu Pedersen Biopharmaceutical

Chengdu Pedersen Biopharmaceutical is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of innovative therapies for metabolic diseases. The company focuses on the design and optimization of peptide-based drugs, particularly multi-receptor agonists targeting GLP-1, GIP, and Glucagon receptors. Their lead programs aim to address significant unmet needs in type 2 diabetes, chronic weight management, and metabolic liver diseases. By leveraging advanced peptide engineering, Pedersen Biopharmaceutical seeks to develop next-generation treatments with improved efficacy and safety profiles compared to existing metabolic therapies.